206 related articles for article (PubMed ID: 32734834)
1. Clinical significance of circPVT1 in patients with non-small cell lung cancer who received cisplatin combined with gemcitabine chemotherapy.
Lu H; Xie X; Chen Q; Cai S; Liu S; Bao C; Luo J; Kong J
Tumori; 2021 Jun; 107(3):204-208. PubMed ID: 32734834
[TBL] [Abstract][Full Text] [Related]
2. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
Wu YL; Zhou C; Lu S; Qin S; Pan H; Wu G; Cheng Y; Liu X; Han B; Zhu Y; Zhong Z; Huang C; Chen L; Liang H; Li E; Jiang G
Lung Cancer; 2019 Apr; 130():18-24. PubMed ID: 30885342
[TBL] [Abstract][Full Text] [Related]
4. Silencing circPVT1 enhances radiosensitivity in non-small cell lung cancer by sponging microRNA-1208.
Huang M; Li T; Wang Q; Li C; Zhou H; Deng S; Lv Z; He Y; Hou B; Zhu G
Cancer Biomark; 2021; 31(3):263-279. PubMed ID: 33896835
[TBL] [Abstract][Full Text] [Related]
5. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
[TBL] [Abstract][Full Text] [Related]
6. Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial).
Hu L; Liang G; Yuliang W; Bingjing Z; Xiangdong Z; Rufu X
Trials; 2013 Feb; 14():45. PubMed ID: 23413951
[TBL] [Abstract][Full Text] [Related]
7. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
Wang Y; Wen L; Zhao SH; Ai ZH; Guo JZ; Liu WC
Lung Cancer; 2013 Feb; 79(2):173-9. PubMed ID: 23177020
[TBL] [Abstract][Full Text] [Related]
8. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
Mlak R; Krawczyk P; Ciesielka M; Kozioł P; Homa I; Powrózek T; Prendecka M; Milanowski J; Małecka-Massalska T
Clin Transl Oncol; 2016 Sep; 18(9):915-24. PubMed ID: 26650486
[TBL] [Abstract][Full Text] [Related]
9. CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis.
Zheng F; Xu R
Biomed Pharmacother; 2020 Apr; 124():109828. PubMed ID: 31986409
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: a phase II study.
Aydiner A; Kiyik M; Cikrikcioglu S; Kosar F; Gurses A; Turna A; Yazar A; Dilege S; Goksel T; Cakan A
Lung Cancer; 2007 Nov; 58(2):246-52. PubMed ID: 17683827
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study.
Morabito A; Gebbia V; Di Maio M; Cinieri S; Viganò MG; Bianco R; Barbera S; Cavanna L; De Marinis F; Montesarchio V; Costanzo R; Sandomenico C; Montanino A; Mancuso G; Russo P; Nacci A; Giordano P; Daniele G; Piccirillo MC; Rocco G; Gridelli C; Gallo C; Perrone F
Lung Cancer; 2013 Jul; 81(1):77-83. PubMed ID: 23643177
[TBL] [Abstract][Full Text] [Related]
12. Methylation patterns and chemosensitivity in NSCLC.
Ramírez JL; Salazar MF; Gupta J; Sánchez JM; Taron M; Sanchez-Ronco M; Alberola V; De las Peñas R
Adv Exp Med Biol; 2006; 587():195-209. PubMed ID: 17163167
[TBL] [Abstract][Full Text] [Related]
13. Genetic testing for chemotherapy in non-small cell lung cancer.
Rosell R; Taron M; Alberola V; Massuti B; Felip E
Lung Cancer; 2003 Aug; 41 Suppl 1():S97-102. PubMed ID: 12867068
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: A retrospective analysis.
Ma D; Wang J; Hao X; Wang Y; Hu X; Xing P; Li J
Thorac Cancer; 2017 Sep; 8(5):482-488. PubMed ID: 28745824
[TBL] [Abstract][Full Text] [Related]
15. Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
Yan D; Wei P; An G; Chen W
J Cardiothorac Surg; 2013 Jun; 8():149. PubMed ID: 23759026
[TBL] [Abstract][Full Text] [Related]
16. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
Lv C; Ma Y; Feng Q; Fang F; Bai H; Zhao B; Yan S; Wu N; Zheng Q; Li S; Chen J; Wang J; Feng Y; Wang Y; Pei Y; Fang J; Yang Y
World J Surg Oncol; 2013 Apr; 11():96. PubMed ID: 23621919
[TBL] [Abstract][Full Text] [Related]
17. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
Ramirez JL; Rosell R; Taron M; Sanchez-Ronco M; Alberola V; de Las Peñas R; Sanchez JM; Moran T; Camps C; Massuti B; Sanchez JJ; Salazar F; Catot S;
J Clin Oncol; 2005 Dec; 23(36):9105-12. PubMed ID: 16361617
[TBL] [Abstract][Full Text] [Related]
18. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
19. High COL4A3 expression correlates with poor prognosis after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Jiang CP; Wu BH; Chen SP; Fu MY; Yang M; Liu F; Wang BQ
Tumour Biol; 2013 Feb; 34(1):415-20. PubMed ID: 23108892
[TBL] [Abstract][Full Text] [Related]
20. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
